Breast Cancer Mutations <i>HER2V777L</i> and <i>PIK3CAH1047R</i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance - Concepedia

Concepedia

Publication | Open Access

Breast Cancer Mutations <i>HER2V777L</i> and <i>PIK3CAH1047R</i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance

DOI Full Paper Access

29

Citations

47

References

2023

Year

Xiaoqing Cheng, Yirui Sun, Maureen Highkin, Nagalaxmi Vemalapally, Xiaohua Jin, Brandon Zhou, Julie L. Prior, Ashley R. Tipton, Shunqiang Li, Anton Iliuk,

Cancer Research

Abstract

In HER2-mutated breast cancer, PIK3CA mutation activates p21-CDK4/6-cyclin D1 signaling to drive resistance to HER2-targeted therapies, which can be overcome using CDK4/6 inhibitors.

References

	Year	Citations

Page 1